Last reviewed · How we verify
Hepatitis C Translating Initiatives for Depression Into Solutions (HEPTIDES)
Chronic infection with hepatitis C (CHC) is a common and expensive condition, and it disproportionately affects Veterans. Treatment with antiviral therapy reduces liver disease progression and improves health related quality of life. However, \~70% of Veterans with CHC are considered ineligible for antiviral treatment. Most of these patients are excluded due to the presence of co-existing depression and substance use. The proposed project will adapt and adopt an evidence-based collaborative depression care model in CHC clinics. By removing the leading contraindication for antiviral treatment, this project will potentially yield benefits that go far beyond the obvious quality of life benefit from antidepressant therapy itself.
Details
| Lead sponsor | VA Office of Research and Development |
|---|---|
| Phase | NA |
| Status | COMPLETED |
| Enrolment | 309 |
| Start date | 2012-02 |
| Completion | 2015-11 |
Conditions
- Hepatitis C
- Depression
Interventions
- Depression collaborative care model
Primary outcomes
- Number of Patients Who Initiated Hepatitis C Antiviral Treatment Within 12 Months of Enrollment — 12 months
Antiviral treatment initiation was measured dichotomously by assigning a value of 1 if the patient received at least one prescription of interferon within 12 months of enrollment, and a value of 0 otherwise. - Depression Care: Treatment Response — Baseline and 12 months
Depression outcomes were assessed using the item mean score from the 20-item Hopkins Symptom Checklist (SCL-20) collected at baseline and 12-months. The SLC-20 items are scored from 0 to 4 and averaged to provide a mean depression severity score ranging from 0 to 4. Depression treatment response was defined as a 50% or greater decrease in the mean SCL-20 score compared with baseline. - Depression Care: Depression Remission — Baseline and 12 months
Depression outcomes were assessed using the item mean score from the 20-item Hopkins Symptom Checklist (SCL-20) collected at baseline and 12-months. The SLC-20 items are scored from 0 to 4 and averaged to provide a mean depression severity score ranging from 0 to 4. Remission was defined as an item mean SCL-20 score of less than 0.5. - Depression Care: Change From Baseline in Number of Depression Free Days (DFDs) at 12 Months — From Baseline to 12 months
The change in Depression Free Days was assessed using the item mean score from the 20-item Hopkins Symptom Checklist (SCL-20) collected at baseline and 12-months. The SLC-20 items are scored from 0 to 4 and averaged to provide a mean depression severity score ranging from 0 to 4. Depression-free days (DFDs) were calculated using an SCL-20 score of less than 0.5 for depression-free and 2.0 or higher for fully symptomatic, and scores in between were assigned a linear proportional value.
Countries
United States